# Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects

> **NCT01691872** · PHASE1 · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Epilepsy, Partial

## Interventions

- **DRUG:** Retigabine

## Key facts

- **NCT ID:** NCT01691872
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-10-10
- **Primary completion:** 2012-10-18
- **Final completion:** 2012-10-18
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Development plan of retigabine XR in Japan was readjusted.
- **Last updated:** 2018-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01691872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01691872, "Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01691872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*